Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Return on Equity: 2017-2025

Historic Return on Equity for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to -0.74%.

  • Rocket Pharmaceuticals' Return on Equity rose 1.00% to -0.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.74%, marking a year-over-year increase of 1.00%. This contributed to the annual value of -0.56% for FY2024, which is 4.00% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Return on Equity stood at -0.74%, which was down 7.57% from -0.69% recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Return on Equity ranged from a high of -0.31% in Q1 2021 and a low of -0.75% during Q3 2024.
  • Over the past 3 years, Rocket Pharmaceuticals' median Return on Equity value was -0.61% (recorded in 2025), while the average stood at -0.62%.
  • In the last 5 years, Rocket Pharmaceuticals' Return on Equity rose by 2bps in 2021 and then dropped by 20bps in 2024.
  • Rocket Pharmaceuticals' Return on Equity (Quarterly) stood at -0.36% in 2021, then dropped by 16bps to -0.52% in 2022, then increased by 2bps to -0.50% in 2023, then fell by 18bps to -0.67% in 2024, then rose by 1bps to -0.74% in 2025.
  • Its Return on Equity stands at -0.74% for Q3 2025, versus -0.69% for Q2 2025 and -0.61% for Q1 2025.